CN117615754A - 包含丁丙诺啡和纳洛酮的胃驻留系统 - Google Patents
包含丁丙诺啡和纳洛酮的胃驻留系统 Download PDFInfo
- Publication number
- CN117615754A CN117615754A CN202280045497.1A CN202280045497A CN117615754A CN 117615754 A CN117615754 A CN 117615754A CN 202280045497 A CN202280045497 A CN 202280045497A CN 117615754 A CN117615754 A CN 117615754A
- Authority
- CN
- China
- Prior art keywords
- segment
- drug eluting
- arms
- naloxone
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163184734P | 2021-05-05 | 2021-05-05 | |
| US63/184,734 | 2021-05-05 | ||
| PCT/US2022/072114 WO2022236288A1 (en) | 2021-05-05 | 2022-05-04 | Gastric residence systems comprising buprenorphine and naloxone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117615754A true CN117615754A (zh) | 2024-02-27 |
Family
ID=83932451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280045497.1A Pending CN117615754A (zh) | 2021-05-05 | 2022-05-04 | 包含丁丙诺啡和纳洛酮的胃驻留系统 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240252483A1 (enExample) |
| EP (1) | EP4333823A4 (enExample) |
| JP (1) | JP2024518156A (enExample) |
| CN (1) | CN117615754A (enExample) |
| AU (1) | AU2022270752A1 (enExample) |
| CA (1) | CA3217611A1 (enExample) |
| IL (1) | IL308210A (enExample) |
| WO (1) | WO2022236288A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117855A1 (en) | 2018-12-03 | 2020-06-11 | Lyndra, Inc. | Stomach simulating device |
| BR112021018496A2 (pt) | 2019-03-20 | 2021-11-30 | Lyndra Therapeutics Inc | Cápsulas e revestimento de cápsula para formas de dosagem de residência gástrica |
| AU2020242062B2 (en) | 2019-03-20 | 2025-12-11 | Nortiva Bio, Inc. | Coatings for gastric residence dosage forms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| US20110033542A1 (en) * | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US8475832B2 (en) * | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| JP6210988B2 (ja) * | 2011-09-19 | 2017-10-11 | オレクソ・アクチエボラゲット | オピオイド依存を治療するための新規乱用耐性医薬組成物 |
| US9687445B2 (en) * | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
| NZ727659A (en) * | 2014-06-11 | 2021-12-24 | Massachusetts Inst Technology | Residence structures and related methods |
| US11576859B2 (en) * | 2015-10-23 | 2023-02-14 | Lyndra Therapeutics, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| CN109310639A (zh) * | 2016-05-27 | 2019-02-05 | 林德拉有限公司 | 用于胃驻留系统的材料结构 |
| JP2019532947A (ja) * | 2016-09-30 | 2019-11-14 | リンドラ,インコーポレイティド | アダマンタン系薬物の持続的送達のための胃内滞留システム |
| CA3066658A1 (en) * | 2017-06-09 | 2018-12-13 | Lyndra, Inc. | Gastric residence systems with release rate-modulating films |
-
2022
- 2022-05-04 WO PCT/US2022/072114 patent/WO2022236288A1/en not_active Ceased
- 2022-05-04 IL IL308210A patent/IL308210A/en unknown
- 2022-05-04 AU AU2022270752A patent/AU2022270752A1/en active Pending
- 2022-05-04 CA CA3217611A patent/CA3217611A1/en active Pending
- 2022-05-04 EP EP22799800.2A patent/EP4333823A4/en active Pending
- 2022-05-04 CN CN202280045497.1A patent/CN117615754A/zh active Pending
- 2022-05-04 US US18/289,331 patent/US20240252483A1/en active Pending
- 2022-05-04 JP JP2023568023A patent/JP2024518156A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308210A (en) | 2024-01-01 |
| US20240252483A1 (en) | 2024-08-01 |
| CA3217611A1 (en) | 2022-11-10 |
| JP2024518156A (ja) | 2024-04-25 |
| EP4333823A1 (en) | 2024-03-13 |
| AU2022270752A1 (en) | 2023-12-07 |
| EP4333823A4 (en) | 2025-04-09 |
| WO2022236288A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117615754A (zh) | 包含丁丙诺啡和纳洛酮的胃驻留系统 | |
| JP6550157B2 (ja) | Gaba類似体及びオピオイドを含む新規胃内滞留型剤形 | |
| JP2024503485A (ja) | リスペリドンを投与するための胃内滞留システム | |
| CN117615755A (zh) | 包含美沙酮的胃驻留系统 | |
| US20080176955A1 (en) | Combined administration of benzonatate and guaifenesin | |
| KR20150029762A (ko) | 약제학적 조성물 | |
| JP2010534721A (ja) | パルス型胃滞留性製剤 | |
| BRPI0618502A2 (pt) | forma farmacêutica oral de micropartìculas contra mau uso | |
| JP2005507000A (ja) | 下部胃腸管において制限された薬物放出性を有する胃保持性経口投薬形態 | |
| US20250339368A1 (en) | Dosage forms for gastric retention | |
| CN120303029A (zh) | 使用胃驻留系统的利培酮剂量方案 | |
| CN117083059A (zh) | 用于利培酮施用的胃滞留系统 | |
| CN118871091A (zh) | 用于胃滞留的剂型 | |
| TW202500122A (zh) | 用於胃滯留系統之材料架構 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |